Molecular markers for breast cancer diagnosis, prognosis and targeted therapy-Reference-Cited by-同舟云学术

Molecular markers for breast cancer diagnosis, prognosis and targeted therapy

Published:2014-08-05 Issue:1 Volume:111 Page:81-90
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J. Surg. Oncol.

Author:

Lang Julie E.¹,Wecsler Julie S.¹,Press Michael F.²,Tripathy Debasish³

Affiliation:

1. University of Southern California Department of Surgery; Division of Breast and Soft Tissue Surgery; Norris Comprehensive Cancer Center; Los Angeles California

2. University of Southern California Department of Pathology; Norris Comprehensive Cancer Center; Los Angeles California

3. University of Southern California Department of Medicine; Division of Oncology; Norris Comprehensive Cancer Center; Los Angeles California

Funder

National Cancer Institute

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Reference105 articles.

1. Publication of tumor marker research results: The necessity for complete and transparent reporting;McShane;J Clin Oncol,2012

2. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer;Harris;J Clin Oncol,2007

3. Building a personalized medicine infrastructure at a major cancer center;Meric-Bernstam;J Clin Oncol,2013

4. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors;Fisher;N Engl J Med,1989

5. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial;Cuzick;Lancet Oncol,2010

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of mitophagy-related subtypes of breast cancer and the association with immune related characteristics;Heliyon;2023-12

2. Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines;Biomedicines;2023-08-28

3. Circ_PRDM5/miR‐25‐3p/ANKRD46 axis is associated with cell malignant behaviors in subjects with breast cancer evaluated by ultrasound;Journal of Biochemical and Molecular Toxicology;2023-07-23

4. Immunoprofiling of BRAFV600E in Precancerous and Cancerous Lesions of Breast by Immunohistochemistry and its Association with Clinicopathological Features;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2023

5. Insilico-based identification of survival-associated lncRNAs, mRNAs and, miRNAs in breast cancer;2022-12-29